US5280040A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Methods for reducing bone loss using centchroman derivatives
Assignee: Zymogenetics Inc
•
Filing: 1993-03-11
•
Granted: 1994-01-18
•
Expires: 2013-03-11
Abstract
Abstract Methods and pharmaceutical compositions for reducing bone loss are disclosed. 3,4-diarylchromans and their pharmaceutically acceptable salts are formulated into medicaments for the treatment of bone loss due to osteoporosis or other conditions. An exemplary 3,4-diarylchroman is centchroman (3,4-trans-2,2-dimethyl-3-phenyl-4-[p-(beta-pyrrolidinoethoxy)phenyl]-7-methoxy-chroman). Formulations include tablets and other forms suitable for oral administration and controlled-release subdermal implants.
Inventors
- 👤 Virender M. Labroo
- 👤 James R. Piggott
- 👤 Steven D. Bain
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 03:38
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/335; A61K31/35; A61K31/395; A61K31/40; A61P; A61P19/00; A61P19/08; A61P19/10
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
63 words
A method for treating osteoporosis comprising administering to a patient a bone loss inhibiting compound of the formula ##STR3## or a pharmaceutically acceptable salt thereof, wherein R1, R4 and R5 are individually hydrogen, hydroxy, halo, trifluoromethyl, lower alkyl, lower alkoxy or tertiary amino lower alkoxy; and R2 and R3 are individually hydrogen or lower alkyl, in an amount sufficient to inhibit bone resorption.
Claim 2
Independent Claim
63 words
A method for treating osteoporosis comprising administering to a patient a bone loss inhibiting compound of the formula ##STR3## or a pharmaceutically acceptable salt thereof, wherein R1, R4 and R5 are individually hydrogen, hydroxy, halo, trifluoromethyl, lower alkyl, lower alkoxy or tertiary amino lower alkoxy; and R2 and R3 are individually hydrogen or lower alkyl, in an amount sufficient to inhibit bone resorption.
Claim 3
Dependent Claim
11 words
A method according to claim 1 wherein said compound is ##STR4##
Claim 4
Dependent Claim
19 words
A method according to claim 1 wherein said compound is administered at a dose of 0.1-5.0 mg/kg patient weight/day.
Claim 5
Dependent Claim
27 words
A method according to claim 1 wherein R1 is lower alkoxy, R2 and R3 are lower alkyl, R4 is hydrogen and R5 is tertiary amino lower alkoxy.
Claim 6
Dependent Claim
10 words
A method according to claim 1 wherein R1 is methoxy.
Claim 7
Dependent Claim
12 words
A method according to claim 1 wherein R2 and R3 are methyl.
Claim 8
Dependent Claim
10 words
A method according to claim 1 wherein R4 is hydrogen.
Claim 9
Dependent Claim
10 words
A method according to claim 1 wherein R5 is ##STR5##
Claim 10
Dependent Claim
11 words
A method according to claim 1 wherein said compound is ##STR6##
Claim 11
Dependent Claim
13 words
A method according to claim 1 wherein said patient is a post-menopausal female.
Claim 12
Dependent Claim
17 words
A method according to claim 1 wherein said composition is in a form suitable for oral administration.
Claim 13
Dependent Claim
16 words
A method according to claim 1 wherein said composition is administered at daily to weekly intervals.
Claim 14
Dependent Claim
17 words
A method according to claim 1 wherein said composition is in the form of a subdermal implant.
References Cited (Backward Citations)
US3340276A
Cited
US3822287A
Cited
US4210644A
Cited
US4447622A
Cited
US4489056A
Cited
US4882347A
Cited
US5015661A
Cited
US5063234A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1997-01-17 | 1997-07-19 | 1998-01-18 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2001-01-17 | 2001-07-19 | 2002-01-18 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2005-01-17 | 2005-07-19 | 2006-01-18 | $7700.00 | Window Closed / Lapsed |